GLCCI1基因多态性与吸入性糖皮质激素治疗慢性气道疾病疗效的研究进展
Research Progress of GLCCI1 Gene Polymorphism and the Efficacy of Inhaled Glucocorticoids in the Treatment of Chronic Airway Diseases
DOI: 10.12677/ACM.2022.1291252, PDF,    科研立项经费支持
作者: 王 珏*, 权瑞宇：西安医学院，陕西 西安；丁 琦, 魏 霞#：西安市第九医院呼吸与危重症医学科，陕西 西安
关键词: 支气管哮喘；慢性阻塞性肺疾病；吸入性糖皮质激素；GLCCI1基因多态性；精准医学；Bronchial Asthma； Chronic Obstructive Pulmonary Disease； Inhaled Glucocorticoids； GLCCI1 Gene Polymorphism； Precision Medicine
摘要: 支气管哮喘(哮喘)和慢性阻塞性肺疾病(慢阻肺)是临床上常见的慢性气道炎症性疾病，均可出现气流受限的病理生理学改变。吸入性糖皮质激素(ICS)在慢性气道疾病的治疗中发挥重要的抗炎作用。研究发现慢阻肺和哮喘患者对ICS的治疗反应存在个体差异。糖皮质激素诱导转录因子1基因(GLCCI1)是糖皮质激素生物合成通路上的一个诱导基因，其基因多态性能够影响这两类慢性气道疾病对ICS治疗的反应性。本文对近年关于GLCCI1基因多态性与ICS治疗哮喘和慢阻肺疗效的研究进展作一综述，旨在为ICS的精准治疗提供新思路。
Abstract: Bronchial asthma (asthma) and chronic obstructive pulmonary disease (COPD) are common clinical chronic airway inflammatory diseases, both of which can present pathophysiological changes of air-flow limitation. Inhaled corticosteroids (ICS) play an important anti-inflammatory role in the treat-ment of chronic airway disease. Studies have found individual differences in the response of COPD and asthma patients to ICS treatment. Glucocorticoid-inducible transcription factor 1 gene (GLCCI1) is an inducible gene in the glucocorticoid biosynthesis pathway, and its gene polymorphism can af-fect the responsiveness of these two types of chronic airway diseases to ICS therapy. This article re-views the recent research progress on GLCCI1 gene polymorphism and the efficacy of ICS in the treatment of asthma and COPD, aiming to provide new ideas for the precise treatment of ICS.
文章引用：王珏, 丁琦, 权瑞宇, 魏霞. GLCCI1基因多态性与吸入性糖皮质激素治疗慢性气道疾病疗效的研究进展[J]. 临床医学进展, 2022, 12(9): 8671-8677. https://doi.org/10.12677/ACM.2022.1291252

参考文献

[1] Huang, K., Yang, T., Xu, J., et al. (2019) Prevalence, Risk Factors, and Management of Asthma in China: A National Cross-Sectional Study. The Lancet, 394, 407-418. [Google Scholar] [CrossRef] 
[2] Wang, C., Xu, J., Yang, L., et al. (2018) Prevalence and Risk Factors of Chronic Obstructive Pulmonary Disease in China (The China Pulmonary Health [CPH] Study): A National Cross-Sectional Study. The Lancet, 391, 1706-1717. [Google Scholar] [CrossRef] 
[3] 朱琳, 邓婕, 宋洪涛. 抗哮喘药的药物基因组学研究进展[J]. 中国医院药学杂志, 2011, 31(10): 856-859.
[4] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组, 中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会. 慢性阻塞性肺疾病诊治指南(2021年修订版) [J]. 中华结核和呼吸杂志, 2021, 44(3): 170-205. [Google Scholar] [CrossRef] [PubMed]
[5] Pinto, C.R., Almeida, N.R., Marques, T.S., et al. (2013) Local Adverse Effects Associated with the Use of Inhaled Corticosteroids in Patients with Moderate or Severe Asthma. Jornal Brasileiro de Pneumologia, 39, 409-417. [Google Scholar] [CrossRef] 
[6] Eric, B., Tim, H., Santiago, Q., et al. (2011) Overall Asthma Control Achieved with Budesonide/Formoterol Maintenance and Reliever Therapy for Patients on Different Treatment Steps. Respiratory Research, 12, Article No. 38. [Google Scholar] [CrossRef] [PubMed]
[7] Mathioudakis, A.G., Amanetopoulou, S.G., Gialmanidis, I.P., et al. (2013) Impact of Long-Term Treatment with Low-Dose Inhaled Corticosteroids on the Bone Mineral Density of Chronic Obstructive Pulmonary Disease Patients: Aggravating or Beneficial? Respirology: Official Journal of the Asian Pacific Society of Respirology, 18, 147-153. [Google Scholar] [CrossRef] [PubMed]
[8] Ozlem, K., Niloufar, F., Esra, B., et al. (2019) Genetic As-sociations of the Response to Inhaled Corticosteroids in Asthma: A Systematic Review. Clinical and Translational Al-lergy, 9, Article No. 2. [Google Scholar] [CrossRef] [PubMed]
[9] 朱丽丽, 张海邻, 李昌崇. 糖皮质激素抗支气管哮喘治疗的药物基因组学研究进展[J]. 国际呼吸杂志, 2017, 37(1): 51-56. [Google Scholar] [CrossRef] 
[10] 洪菲萍, 杨一民. 糖皮质激素治疗支气管哮喘的药物基因组学研究进展[J]. 广西医学, 2020, 42(7): 879-882.
[11] 荀秋芬, 胡成平. 支气管哮喘患者吸入性糖皮质激素疗效与基因多态性研究进展[J]. 国际呼吸杂志, 2016, 36(21): 1670-1673. [Google Scholar] [CrossRef] 
[12] 任丹阳, 李云巍, 涂彩霞, 等. ADRB2、GLCCI1、FCER2基因检测在2例难治性哮喘患儿个体化用药中的实践[J]. 中国药房, 2018, 29(5): 659-662. [Google Scholar] [CrossRef] 
[13] 张微, 冯琳琳, 平昭. 单核苷酸多态性检测技术研究进展[J]. 生物技术通讯, 2016, 27(6): 879-883. [Google Scholar] [CrossRef] 
[14] Al-Romaih, K.I., Genovese, G., Al-Mojalli, H., et al. (2011) Genetic Diagnosis in Consanguineous Families with Kidney Disease by Homozygosity Mapping Coupled with Whole-Exome Sequencing. American Journal of Kidney Diseases: The Official Journal of the National Kidney Founda-tion, 58, 186-195. [Google Scholar] [CrossRef] [PubMed]
[15] Tantisira, K.G., Damask, A., Szefler, S.J., et al. (2012) Ge-nome-Wide Association Identifies the T Gene as a Novel Asthma Pharmacogenetic Locus. American Journal of Respir-atory and Critical Care Medicine, 185, 1286-1291. [Google Scholar] [CrossRef] 
[16] Palmer, L.J., Silverman, E.S., Weiss, S.T., et al. (2002) Phar-macogenetics of Asthma. American Journal of Respiratory and Critical Care Medicine, 165, 861-866. [Google Scholar] [CrossRef] [PubMed]
[17] Hersh, C.P. (2019) Pharmacogenomics of Chronic Obstructive Pulmonary Disease. Expert Review of Respiratory Medicine, 13, 459-470. [Google Scholar] [CrossRef] [PubMed]
[18] Tantisira, K.G., Lasky-Su, J., Harada, M., et al. (2011) Ge-nomewide Association between GLCCI1 and Response to Glucocorticoid Therapy in Asthma. The New England Journal of Medicine, 365, 1173-1183. [Google Scholar] [CrossRef] 
[19] 许玉竹. GLCCI1基因多态性与哮喘患者吸入型糖皮质激素的治疗反应性的相关性研究[D]: [硕士学位论文]. 武汉: 华中科技大学, 2014.[CrossRef] 
[20] 郝珉, 路苓, 李媛媛, 等. GLCCI1和CRHR1基因单核苷酸多态性对支气管哮喘患儿吸入糖皮质激素后肺功能的影响[J]. 当代医学, 2020, 26(35): 120-122. [Google Scholar] [CrossRef] 
[21] KIzuhara, Y., Matsumoto, H., Kanemitsu, Y., et al. (2014) GLCCI1 Variant Accelerates Pulmonary Function Decline in Patients with Asthma Receiving Inhaled Cortico-steroids. Allergy, 69, 668-673. [Google Scholar] [CrossRef] [PubMed]
[22] 周淑新. WONCA研究论文摘要汇编——GLCCI1与糖皮质激素哮喘疗法反应的基因组相关[J]. 中国全科医学, 2011, 14(36): 4227.
[23] 丁颖, 陆敏, 董晓艳, 等. GLCCI1基因多态性对吸入型糖皮质激素治疗儿童哮喘疗效的影响[J]. 中国临床药学杂志, 2017, 26(6): 353-358.
[24] Hu, C.P., Xun, Q.F., Li, X.Z., et al. (2016) GLCCI1 Variation Is Associated with Asthma Suscep-tibility and Inhaled Corticosteroid Response in a Chinese Han Population. Archives of Medical Research, 47, 118-125. [Google Scholar] [CrossRef] [PubMed]
[25] 朱双桂, 陈强, 万慕湲, 等. 儿童哮喘吸入性糖皮质激素疗效评价与GLCCI1、FCER2基因多态性的研究[J]. 中国医学创新, 2021, 18(14): 118-123. [Google Scholar] [CrossRef] 
[26] 李晓辉, 李奕, 赵二要. GLCCI1基因rs37973位点多态性与支气管哮喘患儿糖皮质激素治疗效果及肺功能的关系[J]. 中国合理用药探索, 2021, 18(10): 51-55. [Google Scholar] [CrossRef] 
[27] 邱玉明, 李剑雄, 李慧. 153例汉族哮喘患者GLCCI1基因rs37973位点多态性及吸入糖皮质激素治疗反应[J]. 山东医药, 2016, 56(39): 94-96. [Google Scholar] [CrossRef] 
[28] 王星翘, 尹琴, 王天祺, 等. 哮喘患者GLCCI1基因检测指导吸入糖皮质激素的安全性用药效果[J]. 实用临床医药杂志, 2017, 21(1): 34-36. [Google Scholar] [CrossRef] 
[29] 李静, 马丽娟, 袁圆, 等. 吸入性糖皮质激素布地奈德相关基因多态性与哮喘疗效的关系[J]. 中国临床药理学与治疗学, 2021, 26(11): 1250-1258. [Google Scholar] [CrossRef] 
[30] Sakornsakolpat, P., Prokopenko, D., Lamontagne, M., et al. (2019) Genetic Landscape of Chronic Obstructive Pulmonary Disease Identifies Heterogeneous Cell-Type and Phenotype Associations. Nature Genetics, 51, 494-505.
[31] Hersh, C.P. (2017) Diagnosing alpha-1 Antitrypsin Defi-ciency: The First Step in Precision Medicine. F1000Research, 6, Article No. 2049. [Google Scholar] [CrossRef] [PubMed]
[32] Chapman, K.R., Burdon, J.G.W., Piitulainen, E., et al. (2015) Intravenous Augmentation Treatment and Lung Density in Severe α1 Antitrypsin Deficiency (RAPID): A Randomised, Double-Blind, Placebo-Controlled Trial. The Lancet, 386, 360-368. [Google Scholar] [CrossRef] 
[33] van den Berge, M., Hiemstra, P.S. and Postma, D.S. (2011) Genetics of Glucocorticoids in Asthma. The New England Journal of Medicine, 365, 2434-2435. [Google Scholar] [CrossRef] 
[34] Lei, Y., Gao, Y.P., Chen, J.K., et al. (2017) GLCCI1 rs37973: A Potential Genetic Predictor of Therapeutic Response to Inhaled Corticosteroids in Chinese Chronic Obstructive Pulmo-nary Disease Patients. Scientific Reports, 10, Article No. 42552. [Google Scholar] [CrossRef] [PubMed]
[35] Singh, D., Bafadhel, M., Brightling, C.E., et al. (2020) Blood Eosinophil Counts in Clinical Trials for Chronic Obstructive Pulmo-nary Disease. American Journal of Respiratory and Critical Care Medicine, 202, 660-671. [Google Scholar] [CrossRef] 
[36] Hastie, A.T., Martinez, F.J., Curtis, J.L., et al. (2017) Associa-tion of Sputum and Blood Eosinophil Concentrations with Clinical Measures of COPD Severity: An Analysis of the SPIROMICS Cohort. The Lancet Respiratory Medicine, 5, 956-967. [Google Scholar] [CrossRef] 
[37] Zysman, M., Deslee, G., Caillaud, D., et al. (2017) Rela-tionship between Blood Eosinophils, Clinical Characteristics, and Mortality in Patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease, 20, 1819-1824. [Google Scholar] [CrossRef] 

为你推荐